Influence of Probenecid and Quinine on the Pharmacokinetics of Azidothymidine

Completed · Not applicable

Conditions studied: HIV Infections

In brief

Part I studies the effect of quinine on how zidovudine (AZT) is used by the body and eliminated through the kidneys in HIV infected patients. Part II studies the effect of probenecid and quinine on the same aspects. Because AZT leaves the bloodstream quickly, patients must take the drug frequently to keep adequate amounts in their bodies. Probenecid and quinine may slow down the rate at which AZT leaves the body. Therefore, taking these drugs along with AZT may reduce the amount of AZT needed for treatment.

Key facts

Study ID

NCT00000706

Run by

National Institute of Allergy and Infectious Diseases (NIAID)

People needed

12

Expected to finish

1988-12-01

Last updated by the study team

2021-11-03

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients must:
• Have symptomatic HIV infection.
• Be taking zidovudine (AZT), 100 or 200 mg, 5 or 6 x/day.
• Allowed:
• History of Pneumocystis carinii pneumonia (PCP).
• Advanced AIDS related complex (ARC).
• HIV antibody positive with an absolute CD4 lymphocyte count of < 200 cells/mm3 before study entry.

You may not qualify if…

• Co-existing Condition:
• Patients with any of the following conditions are excluded:
• Glucose-6-phosphate dehydrogenase deficiency.
• Allergy to sulfa drugs, probenecid, or quinine.
• Concurrent Medication:
• Excluded:
• Other drugs that might influence the metabolism or renal excretion of zidovudine (AZT).

Where it is running

• Johns Hopkins Hosp — Baltimore, Maryland, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.